K. Ochmann

Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients

W Mück, Ingrid Mai, Lutz Fritsche et al. · Clinical Pharmacology & Therapeutics · 1999 · 157 citations

Cerivastatin Systemic Exposure, Transplantation Medicine, Pharmacotherapy +22

Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin

Wolfgang Mück, K. Ochmann, G. Rohde et al. · European Journal of Clinical Pharmacology · 1998 · 53 citations

Medicine, Pharmacotherapy, Antimicrobial Pharmacokinetics +4

Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.

Wolfgang Mück, W. Ritter, K. Ochmann et al. · PubMed · 1997 · 53 citations

Lipid Peroxidation, Tablet Drug Formulation, Pharmacotherapy +18

Evaluation of the Influence of Antacids and H2 Antagonists on the Absorption of Moxifloxacin after Oral Administration of a 400mg Dose to Healthy Volunteers

Michael-Friedrich B ttcher, K. Ochmann · Clinical Pharmacokinetics · 2001 · 46 citations

Pharmacological Study, Healthy Volunteers, Pharmacology +8

Biopharmaceutical Profile of Cerivastatin: A Novel HMG-CoA Reductase Inhibitor

Wolfgang Mück, K. Ochmann, A. Mazzu et al. · Journal of International Medical Research · 1999 · 16 citations